Lilly Executive and Leadership Team

Axel Hoos, the Chief Executive Officer at Lilly, directs the company's overarching strategy and global operations. Hoos guides Lilly's commitment to discovering, developing, and delivering innovative medicines that address significant unmet medical needs. This leadership role involves setting the strategic vision for the biopharmaceutical firm, ensuring alignment across all departments, and fostering a culture of scientific excellence and patient-centricity. Hoos's oversight extends to critical areas such as research and development pipelines, manufacturing capabilities, and commercialization efforts. The Chief Executive Officer ensures Lilly's continued growth and impact in key therapeutic areas including diabetes, oncology, immunology, and neuroscience, driving forward the company's mission to improve lives worldwide. Axel Hoos is accountable for the firm's financial performance and long-term sustainability, navigating complex regulatory landscapes and market dynamics to achieve corporate objectives.

Mark Stempel, the Senior Vice President - Chief Financial Officer Lilly USA at Lilly, oversees the financial operations and strategic financial planning for Lilly's United States business. Stempel manages all aspects of financial reporting, budgeting, forecasting, and capital allocation to support the company's growth objectives in the U.S. market. This senior leadership role involves ensuring financial integrity, optimizing resource deployment, and driving financial performance across Lilly USA's operations. The Senior Vice President - Chief Financial Officer Lilly USA collaborates with business unit leaders to provide financial insights and guidance, supporting key strategic decisions. Mark Stempel's financial acumen is essential for navigating the complex U.S. healthcare market, managing costs, and maximizing profitability. This position is critical for maintaining Lilly's financial health and supporting its mission to deliver innovative medicines.

Walid Essam, the Director, Finance & Chief Financial Officer, Short Term Assignment at Lilly, provides critical financial leadership and oversight during a defined period. Essam manages financial planning, analysis, and reporting, ensuring fiscal responsibility and strategic alignment for the assigned business units or projects. This role requires adaptability and a comprehensive understanding of financial operations to support Lilly's objectives effectively. The Director, Finance & Chief Financial Officer, Short Term Assignment collaborates with various stakeholders to provide financial insights, drive efficiency, and support decision-making processes. Walid Essam's expertise ensures that financial resources are managed optimally, contributing to the company's overall financial health and operational success during the assignment duration.

Soniya Rai, the Chief Operating Officer, Ibu Development Immunology at Lilly, manages the operational execution of the company's immunology development programs. Rai ensures the efficient and effective progression of drug candidates through the development lifecycle, from preclinical research to clinical trials and regulatory submission. This critical role involves overseeing project management, resource allocation, and cross-functional team coordination within the immunology therapeutic area. The Chief Operating Officer, Ibu Development Immunology works to optimize development processes, mitigate risks, and accelerate timelines to bring vital treatments to patients. Soniya Rai's operational expertise is key to advancing Lilly's pipeline in immunology, a complex and rapidly evolving field. This leadership position drives the operational excellence required to translate scientific discoveries into life-changing therapies for individuals with immune-related conditions.

Stephanie Brennan, the Global Chief Operating Officer, Medical Affairs, Immunology Heor at Lilly, directs the operational execution of medical affairs strategies globally, with a specific focus on immunology and Health Economics and Outcomes Research (HEOR). Brennan ensures the efficient and effective implementation of medical affairs activities, including clinical research support, scientific exchange, and real-world evidence generation. This role is pivotal in translating scientific insights into value demonstration for Lilly's immunology portfolio. The Global Chief Operating Officer, Medical Affairs, Immunology Heor oversees cross-functional collaboration between medical, R&D, and commercial teams to support product lifecycle management and market access. Stephanie Brennan's operational leadership drives the strategic objectives of medical affairs, ensuring Lilly's scientific contributions are effectively communicated and recognized in the global healthcare landscape.

Delia Dragon, the Executive Director and Chief Operating Officer Eli Lilly SSC at Lilly, directs the operational activities and strategic execution for the Eli Lilly Shared Services Company (SSC). Dragon oversees the efficient delivery of essential business support functions, ensuring operational excellence and cost-effectiveness across the organization. This leadership role involves managing diverse teams and processes to provide seamless support to Lilly's global operations. The Executive Director and Chief Operating Officer Eli Lilly SSC focuses on optimizing service delivery, implementing best practices, and driving continuous improvement within the shared services environment. Delia Dragon's operational management is crucial for enabling Lilly's core business functions to operate smoothly and efficiently, contributing to the company's overall success.

Alexandra Frank, the Chief Marketing Officer, Oncology Marketing & Associate at Lilly, spearheads the strategic marketing initiatives for the company's oncology portfolio. Frank develops and executes comprehensive marketing plans designed to reach and serve patients and healthcare providers effectively. This role demands a deep understanding of the oncology landscape, patient journeys, and competitive market dynamics to drive brand awareness and adoption. The Chief Marketing Officer, Oncology Marketing & Associate collaborates closely with commercial, medical, and R&D teams to ensure marketing strategies are aligned with clinical development and patient needs. Alexandra Frank's leadership focuses on communicating the value of Lilly's oncology treatments, expanding market access, and supporting patient access programs. This position is crucial for translating scientific advancements into tangible benefits for patients battling cancer, ensuring Lilly's innovations reach those who need them most.

Robert Petersen, the Chief Revenue Officer, Lilly & Executive at Lilly, directs all revenue-generating activities across the organization. Petersen is responsible for developing and implementing strategies to maximize sales performance and drive top-line growth for Lilly's diverse portfolio of pharmaceutical products. This executive role involves close collaboration with commercial, marketing, and market access teams to identify new revenue opportunities and optimize existing sales channels. The Chief Revenue Officer, Lilly & Executive oversees the sales force, pricing strategies, and commercial operations to ensure consistent revenue generation and market penetration. Robert Petersen's focus is on achieving ambitious financial targets and expanding Lilly's market share globally. This leadership position is instrumental in translating the company's scientific innovations into sustainable commercial success and shareholder value.

Emma Jacob, the Senior Engineer & Chief Marketing Officer, Process Engineering at Lilly, bridges technical engineering expertise with strategic marketing initiatives for process engineering functions. Jacob oversees the development and implementation of marketing strategies that highlight Lilly's advancements in process engineering and manufacturing technologies. This unique dual role requires a deep understanding of both engineering principles and market dynamics to effectively communicate the value of Lilly's operational capabilities. The Senior Engineer & Chief Marketing Officer, Process Engineering collaborates with manufacturing and R&D teams to translate technical innovations into compelling market propositions. Emma Jacob's leadership ensures that Lilly's commitment to efficient and advanced manufacturing processes is recognized and valued by industry stakeholders.

Julio Ger, the Global Chief Marketing Officer, Alliance Management Diabetes & Obesity at Lilly, leads the marketing strategies for the company's diabetes and obesity portfolio, with a specific emphasis on alliance management. Ger develops and executes comprehensive marketing plans to drive market penetration and patient engagement for Lilly's treatments in these critical therapeutic areas. This role involves fostering strategic partnerships and collaborations to expand market reach and therapeutic access. The Global Chief Marketing Officer, Alliance Management Diabetes & Obesity works closely with internal teams and external partners to ensure cohesive and impactful marketing campaigns. Julio Ger's leadership is vital for communicating the value of Lilly's innovations in diabetes and obesity management, supporting patients and healthcare providers worldwide.